

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: **A61K 45/06**

(21) International Application Number: **PCT/EP01/06976**

(22) International Filing Date: **20 June 2001 (20.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). **HABEREY, Martin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIERAUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169 Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/97850 A2

(54) Title: **COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II)**

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. Nature 376, 62-66, 1995), whereas Flt1
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during
10 early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and
25 lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., cell 87, 1171-1180). Conversely, increased vascularization was
30 observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al. Lab.

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendotherial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

- VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).
- 10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
- 15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
- 20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
- 25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

- Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
- 30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).
- Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMABVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.


Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/
 antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,
 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell
 targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-
 5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),
 Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example
 molecules of general formula I

15



20

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

25

R_3 und R_4 a) each independently from each other have the meaning
 of lower alkyl,

9

b) together form a bridge of general partial formula II;




5

m

wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

G

20

A, B, D, E and T

25

wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

- Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or
lower alkyl,
- X has the meaning of imino, oxa or thia;
- 5 Y has the meaning of hydrogen, unsubstituted or substituted
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
- Z has the meaning of amino, mono- or disubstituted amino,
halogen, alkyl, substituted alkyl, hydroxy, etherificated or
esterificated hydroxy, nitro, cyano, carboxy, esterificated
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
15 more than one rest Z is present ($m \geq 2$), the substituents Z are
equal or different from each other, and wherein the bonds
marked with an arrow are single or double bonds; or an N-
oxide of said compound, wherein one or more N-atoms carry
an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.

These compounds can preferentially be used as compound I or II in the inventive
pharmaceutical composition.


25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis,
respectively, which results in a prevention of tumor growth and tumor spread, are
for example

anthranil acid derivatives of general formula IV

30

11



in which

A

has the meaning of group $=NR^2$,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q$, branched or unbranched C_{1-6} -Alkyl or is the group

10




15

or A, Z and R^1 together form the group

20

12



m, n and o

has the meaning of 0 – 3,

q

has the meaning of 1 – 6,

 $R_a, R_b, R_c, R_d, R_e, R_f$

independently from each other have the meaning of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/ or R_a and/ or R_b together with R_c and or R_d or R_c together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R^1 or R^2 ,

X

has the meaning of group $=NR^9$ or $=N-$,

Y

has the meaning of group $-(CH_2)_p$,

p

has the meaning of integer 1-4,

 R^1

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

 R^2

has the meaning of hydrogen or C_{1-6} -alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,


 R^3

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy,

 R^4, R^5, R^6 and R^7

independently from each other have the meaning of hydrogen, halogen or C_{1-6} -alkoxy, C_{1-6} -alkyl or


C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group



- 5 R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.


10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.


More preferentially compounds of general formula V




- 15 in which
R¹ has the meaning of group

20






in which R^5 is chloro, bromo or the group $-OCH_3$,



in which R^7 is $-CH_3$ or chloro,



in which R^8 is -CH₃, fluoro,
chloro or -CF₃


in which R^4 is fluoro,
chloro, bromo, -CF₃,
-N=C, -CH₃, -OCF₃ or
-CH₂OH

in which R^6 is
-CH₃ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their
isomers and salts can be used as compound I or II in the inventive pharmaceutical
composition.

These compounds have the same properties as already mentioned above under
compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in
combination.

The above mentioned compounds are also claimed matter within the inventive
combinations.

20

A further example for ligand binding inhibitors are peptides and DNA sequences
coding for such peptides, which are used for the treatment of angiogeneous
diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59
of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of
main interest.

25

Claimed matter of the instant invention are therefor pharmaceutical compositions

- 5 a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 10 b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 15 c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,
- 20 d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 25 e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 30 f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,
- g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.
For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

Combined functional interference with VEGF/VEGF receptor systems and with
5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to interference with one
ligand/receptor system overlaps with the biological response to interference with a
second ligand/receptor system. Alternatively, combined functional interference
with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via
Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to functional interference with a
ligand/receptor system overlaps in time with targeting of cytotoxic agents.

15 The invention is also directed to a substance which functional interferes with both
VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which
are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor
systems.

20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C,
VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2
(KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1).
Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and
angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal
purposes. Such diseases are, for example, cancer, cancer metastasis,
angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
30 the present invention can be applied orally, parenterally, or via gene therapeutic
methods.

Therefor the present invention also concerns the use of pharmaceutical
compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

15
20

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
 5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
 10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
 15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
 20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

10

15

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

20

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a
5 volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF
10 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

10

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the
 5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of
 15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

20 Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-
 30 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I
10 which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I
which modulates the biological function of one or several of the VEGF/VEGF
receptor systems or of one or several of the Angiopoietin/ Tie receptor systems
and comprising one or several agents as compound II which are targeted to
the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I
which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie
receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound
I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
d) compounds which inhibit or activate expression of a ligand or of a
25 receptor of the VEGF or Tie receptor system,
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor
30 systems,
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- k) delivery systems, such as antibodies, ligands, high-affinity binding
10 oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- l) delivery systems, such as antibodies, ligands, high-affinity binding
15 oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a


14. Pharmaceutical compositions according to claims 1-11 which comprise as

25 compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as

30 compound I and/ or II at least one small molecule of general formula I

41



I,

in which

5

r

has the meaning of 0 to 2,

n

has the meaning of 0 to 2;


R₃ und R₄

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula

II,



II,

15


wherein the binding is via the two terminal C- atoms,
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

5 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;


20 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, 25 carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, 30 phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,
 wherein one or more N-atoms carry an oxygen atom,
 or a salt thereof,

and/or a compound of general formula IV

5



in which

A

has the meaning of group $=NR^2$,

10


W

has the meaning of oxygen, sulfur, two hydrogen atoms
 or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$,
 $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the
 group


15



or A, Z and R^1 together form the group

20


44



5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/ or R _a and/ or R _b together with R _c and or R _d or R _e together with R _e and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
15	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
25	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R⁴, R⁵, R⁶ and R⁷


substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or C₁₋₆-alkoxy, C₁₋₆-alkyl or C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R⁵ and R⁶ together form the group



R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts,

and/ or a compound of general formula V





V,

in which


R¹ has the meaning of group

46




in which R⁵ is chloro, bromo or the group -OCH₃,

5



in which R⁷ is -CH₃ or chloro,



in which R^8 is $-CH_3$, fluoro,
chloro or $-CF_3$


in which R^4 is fluoro,
chloro, bromo, $-CF_3$,
 $-N=C$, $-CH_3$, $-OCF_3$ or
 $-CH_2OH$

in which R^6 is
 $-CH_3$ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their
isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as
compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium
hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF
conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-
phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-
tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not
identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as
5 compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
20. Pharmaceutical compositions according to claims 1-17 which comprise as
10 compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.




Fig. 1




Fig. 2




Fig. 3

BEST AVAILABLE COPY




Fig. 4

BEST AVAILABLE COPY




Fig. 5




Fig. 6

BEST AVAILABLE COPY

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPMLXX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

30

35

40

45

50

55

60

```

ttttacagtt ttccttttct tcagagttaa ttttgaatth tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt tttttttaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaaca gccaataaac cataatggtg ccacagggat ggagcaggga agggcatctc 300
taacgtgtcc tctagtctat ctctgctaaa cagaacccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
aagcaaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctggt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctacgctggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccaaaacgca acctaaccas agcaaatctt 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgtaa gagcatagcg acatcacgtg cgttttctta atgtccctgg tggcggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggagaca 1080
tccgcaaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac ggttacgcgc ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcgatagc tcatttaatg ttaaaccgca tcaggggcct ctccctccgt 1320
ttctgccagg ggtttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcgg tctggctgct tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgacccctc caacaagcat cgcagggcac 1500
tgtcctcggg ggtacagacc gtggtccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgctgtgag gccgtgctgt ctggggctcg aggtctcttc tgctgggtgt 1620
cttggacggg cgggtagtgc tgctgcagag acaaagcatc tccccctccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaaactggc atcattactt ccgttccttc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cggtggacct gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct

```

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct cttaagaccc ctggggcctg tgctacccag 60
 acactaacaa cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tcctgtggcc cattagggaa gtgggtgacct cgggagctat ttgcctgttg 180
 agtgcacaca cctggaacaa tactgctctc attttttcat ccacatcagt gagaaatgag 240
 tggcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
 aaatgtcaag ctttgactga aaactcccg ttttccagtc actggagtgt gtgcgtatga 480
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggccct 540
 cacctcccca tgacatctc catgagcctc ctgatgtagt g

15 <210> 3
 <211> 516
 <212> DNA
 <213> Human

<400> 3

20 tagagatgtt ggttcatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
 tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgcg aacctgaatg 120
 25 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
 tcctgcgcat tgaggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcatcaaca 420
 30 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480
 atgaagttcc agagtttgtt gtgtaaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 35 <213> Human

<400> 4

40 cccacaacac agggggcctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60
 cctgctcact ggtacacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
 ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
 ggggtgcgctc ttggccttgc cgtgccctca tccccgggt gaggcagcga cacagcaggt 240
 gcaccaactc cagcagggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300
 45 tgaagatggt ctctccgtg gggcgagaga caaagcagtc cagcaggtag gggcagggtg 360
 ctgcctggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420
 ggaagcctgc ctctagcaca ctcttgacga gcacactggc gacataggtg cccatcagtg 480
 ctccgcggat gcgcaggcga ccactctctg ccaccgagat cttggccatc tgacgctcta 540
 cggccgccag cgcccgctcc acctgtgggt ccttggccgg cagtggccgc agctccccct 600
 50 ccttctgccc cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660
 ggggtgggtgt gctgacgaag aggaactgca gcacccagta gcggtgtgg gagatgggga 720
 aggcctgggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
 actgctcgtc accccacact gactcgccgg ccaggccag gatgaggatg cggaagatga 840
 agagcaccgt cagccagatc ttaccacca cggtcgagtg ctccctggacc tgggtccagca 900
 55 acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcgga aggagacaga 960
 gcagtcaggt gtgtcagcat ggcactcttc tcgttcgccc agcaacaagc ctgcagggtg 1020
 gtctgccacg ccggttctac cgctgcctg ccgggcggcc cagggtggag tggggacgat 1080
 ggccggagtg acgcccgcg

<210> 5
 60 <211> 1015
 <212> DNA
 <213> Human

<400> 5

65 gaggataggg agcctggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

	aaaaagtgtct	ttttgaaaat	gttgaggttg	aaatgatggg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acacccccct	ggttcgcaca	tgtacaggaa	tgggacccag	180
	ttggggcaca	gccatggact	tccccgccct	ggaatgtgtg	gtgcaaagtg	gggccagggc	240
	ccagacccaa	gaggagaggg	tgggtccgcag	acacccccgg	atgtcagcat	cccccgacct	300
5	gccttctggc	ggcacctccc	gggtgctgtg	ttgagtcagc	aggcatgggg	tgagagcctg	360
	gtatatgtctg	ggaacagggt	gcaggggcca	agcgttcctc	cttcagcctt	gacttgggcc	420
	atgcaccccc	tctcccccaa	acacaaacaa	gcacttctcc	agtatggtgc	caggacaggt	480
	gtcccttcag	tcctctggtt	atgacctcaa	gtcctacttg	ggccctgcag	cccagcctgt	540
	gttgtaacct	ctgcgtcctc	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
10	atcatcattg	ttgctttatc	acttctaaga	cattttgtac	ggcacggaca	agttaaacag	660
	aatgtgcttc	cctcccctgg	gtctcacacg	ctcccacgag	aatgccacag	gggccgtgca	720
	ctgggcaggc	ttctctgtag	aaccccaggg	gcttcggccc	agaccacagc	gtcttgccct	780
	gagcctagag	cagggagtc	cgaactctctg	cattcacaga	ccacctccac	aattgttata	840
	accaaaaggcc	tcctgttctg	ttatttctact	taaatacaaca	tgctattttg	ttttcactca	900
15	cttctgactt	tagcctcgctg	ctgagccgtg	tatccatgca	gtcatgttca	cgtgctagtt	960
	acgtttttct	tcttacacat	gaaaataaat	gcataagtgt	tagaagaaaa	aaaaa	
	<210> 6						
	<211> 2313						
20	<212> DNA						
	<213> Human						
	<400> 6						
25	ccagagcagg	cctgggtgtg	agcagggacg	gtgcaccgga	cggcgggatc	gagcaaattg	60
	gtctggccat	ggagcacgga	gggtcctacg	ctcggggcgg	gggcagctct	cggggctgct	120
	ggattaccct	gcgtactctc	ttcctcttcg	tctccctcat	ccaattcctc	atcatcctgg	180
	ggctcgtgct	cttcatggtc	tatggcaacg	tgcacgtgag	cacagagtcc	aacctgcagg	240
	ccaccgagcg	ccgagccgag	ggcctataca	gtcagctcct	agggctcacg	gcctccagct	300
30	ccaacttgac	caaggagctc	aacttcacca	cccgcgccaa	ggatgccatc	atgcagatgt	360
	ggctgaatgc	tcgcccgcgac	ctggaccgca	tcaatgccag	cttcgccccag	tgccaggggtg	420
	accgggtcat	ctacacgaac	aatcagaggt	acatggctgc	catcatcttg	agtgagaagc	480
	aatgcagaga	tcaattcaag	gacatgaaca	agagctgcga	tgcttctgctc	ttcatgctga	540
	atcagaagggt	gaagacgctg	gaggtggaga	tagccaagga	gaagaccatt	tgactaagg	600
35	ataaggaaag	cgtgctgctg	aacaaacgcg	tggcggagga	acagctgggt	gaatgcgtga	660
	aaacccggga	gctgcagcac	caagagcgcc	actggccaag	gagcaactgc	aaaagggtgca	720
	agccctctgc	ctgccccttg	acaaggacaa	gtttgagatg	gaccttcgta	acctgtggag	780
	ggactccatt	atcccacgca	gcctggacaa	cctgggttac	aacctctacc	atcccctggg	840
	ctcggaattg	gcctccatcc	gcagagcctg	cgaccaatg	cccagcctca	tgagctccaa	900
40	ggtggaggag	ctggcccggg	gcctccgggc	ggatatcgaa	cgcgtggccc	gcgagaactc	960
	agacctccaa	cgccagaagc	tggaaagcca	gcagggcctg	cgggccagtc	aggaggcgaa	1020
	acagaagggtg	gagaaggagg	ctcaggcccc	ggaggccaag	ctccaaagctg	aatgctccc	1080
	gcagaccagc	ctagcgctgg	aggagaaggc	ggtgctgcgg	aaggaaacgag	acaacctggc	1140
	caaggagctg	gaagagaaga	agaggagggc	ggagcagctc	aggatggagc	tggccatcag	1200
45	aaactcagcc	ctggacacct	gcatacaagc	caagtgcgag	ccgatgatgc	cagtgtcaag	1260
	gcccattgggc	cctgtcccca	acccccagcc	catcgaccca	gctagcctgg	aggagttaa	1320
	gaggaagatc	ctggagtccc	agaggcccc	tgcaggcatc	cctgtagccc	catccagtgg	1380
	ctgaggaggc	tccaggcctg	aggaccaagg	gatggcccga	ctcggcggtt	tgccggaggat	1440
50	gcagggatat	gtcacacagc	cccagacaaa	ccccctcccg	ccgcccccaa	ccacccaggg	1500
	ccaccatcag	acaactccct	gcatgcaaac	ccctagtacc	ctctcacacc	cgcaccccg	1560
	cctcacgate	cctcaccag	agcacacggc	cgcggagatg	acgtcacgca	agcaacggcg	1620
	ctgacgtcac	atatcaccgt	ggtgatggcg	tcacgtggcc	atgtagacgt	cacgaagaga	1680
	tatagcgatg	gcgtcgtgca	gatgcagcac	gtcgcacaca	gacatgggga	acttggcatg	1740
55	acgtcacacc	gagatgcagc	aacgacgtca	cgggccatgt	cgacgtcaca	catattaatg	1800
	tcacacagac	gcggcgatgg	catcacacag	acggtgatga	tgctcacacac	agacacagtg	1860
	acaacacaca	ccatgacaac	gacacctata	gatatggcac	caacatcaca	tgacgcgatg	1920
	ccctttcaca	cacactttct	agccaattct	cacctagtgt	cacgttcccc	cgaccctggc	1980
	acacggggcca	aggtatccac	aggatcccat	cccctcccgc	acagccctgg	gccccagcac	2040
	ctcccctcct	ccagcttcc	ggcctcccag	ccacttccct	acccccagtg	cctggacccg	2100
60	gaggtgagaa	caggaagcca	ttcacctccg	ctccttgagc	gtgagtgttt	ccaggacccc	2160
	ctcggggccc	tgagccgggg	gtgaggggtca	cctgttgtcg	ggaggggagc	cactccttct	2220
	cccccaactc	ccagccctgc	ctgtggcccg	ttgaaatgtt	ggtggcactt	aataaatatt	2280
	agtaaatcct	taaaaaaaaa	aaaaaaaaaa	aaa			
65	<210> 7						
	<211> 389						

<212> DNA
<213> Human

<400> 7

5

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagacctgac 120
tattctaaaa tcagatccctt acagatccag atttcaggaa acaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcaccagc tatataatat gaggaagtat 240
10 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa ttttcggga 300
gaacctgag ctattaataa tctatgtggc tagtgcgat atattggctt gaatttgctc 360
tccttttgtg gtgtccagtg ggtaacatc

15

<210> 8
<211> 157
<212> DNA
<213> Human

<400> 8

20

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

25

<210> 9
<211> 561
<212> DNA
<213> Human

30

<400> 9

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa tttcccttgc 120
tgaactgaac tattctgtta catatggttg acaaatctgt gtgttatttc ttttctacct 180
35 accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatattt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgtttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgac 480
40 ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccaat ttctaggaaa a

45

<210> 10
<211> 1508
<212> DNA
<213> Human

<400> 10

cacaaacacg agagactcca cggctctgctt gagcaccgcc agcctcctag gctccagcac 60
tcgcaggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtagcag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgcg gatggcataa tccgggtgca acccaaatct 240
gagctcaagc cagggtgagc taagccactg agcaaggaa atttgggcct gcacgcctac 300
55 aggtgtgagg actgtggcaa gtgcaaatgt aaggagtgc cctaccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgctgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
gggtgcatgt cctctctttt gccttgttta tgggtgtacc ttccagccaa ggggtgctt 600
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaaagt tcccactgtc ccccttagga actttgaaaa accaactatg 720
catcattaat caggaatatt acagtaatga ggattttttt tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgtg gatagtcttt 840
gctgtttgcg gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
65 ctacagctaat ggagctcaaa gtatgagata cagaacttgg tgaccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaa tttttgtttg tgaatagtac ttgcaaaact 1020

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatatttt 1080
 gtatatataa taatatttgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaatat tatactaata tgggtgtacat tcggaagaat gtgaatcaat cagtatgttt 1200
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
 10 ttcattgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320
 attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaataattta 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa
 <210> 11
 <211> 389
 <212> DNA
 <213> Human
 15 <400> 11
 20 gggcaggtga tcagggcaca catttcccg tccattgagac agtagcattc ccggcaccca 60
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cgggtgagaca agtgcccgac 120
 aggatgggtg gccagctga agcacaggcc gctctgactg tcagataaag acagccgtga 180
 gtgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360
 25 acctcggccg cgaccacgct gggatccga
 <210> 12
 <211> 981
 <212> DNA
 <213> Human
 30 <400> 12
 35 tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120
 cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggctattaaa aaccctagtt 240
 taggataaca acatattaat cagggcaaaa tacaaatgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cggttttaca gtgatcatat tatatttcat ttggcagaat 360
 40 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420
 taggataaca ggtctgcctg tttgaagatg aaaaaataa cccattttaa atttgcccta 480
 ctcaatttcc ttctcagtca cattttaact ttttaacagc taatcactcc catctacaga 540
 ttaaggtgta tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagttaaaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 45 cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
 taccaggagc agaaccatta agctggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900
 cactgcatct gcacccagca ccatacctca caggagtoga ctcccacgag ccgcctgtat 960
 50 ataagagttc ttttgatgac g
 <210> 13
 <211> 401
 <212> DNA
 <213> Human
 55 <400> 13
 60 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggg aacactgccc 120
 tctctcccc agagcgaccc cccgggcagg tccggggcca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtgggtcatc cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360
 65 acttcagcat atttagttgt cattaaaatt aagctgatat t
 <210> 14

<211> 1002
<212> DNA
<213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
10 tttgaaaatg ttaaatacaa gtcctattct ctttgtccag ctgggttttag ctagaggtag 180
ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
gaagtaaata tctggggccc atcgacccc cactaagtac tttgtcacca tgttgtatct 300
taaaagtcac ttttactgtt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa cccagtttaa ttcccactt ttttaagtag gcttagcttt gaggatgttt 420
15 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
tactgaaaac aatggtgcca tatgctccaa agacatttcc ccaagataac tgccaaagag 540
ttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
attaatacac ctcaaatgga gtagtaacca agcttttctg cccaggaagt aacaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacattc 720
20 attcaataaa ctaggccaac gctaagtgtc caagccactg tgccagggtat taacaatata 780
acaacaataa aagacacagt ccttcctctc aagggtgttca gtctagtagg gaagatgatt 840
attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaatctct 900
gcctatgttc tcagatattc tgggttaggtc agggagtggga acccaaaatc aattctttta 960
acaaacacta aaggtgattc taacacaggc ggtgtgagga cc

25 <210> 15
<211> 280
<212> DNA
<213> Human

30 <400> 15

cgaggtgggc caccctgtgc tgggtctgaga tttttaaatg aggattacat tatcctatct 60
ataatattcc tattctaatac tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
35 aactgtatta tgactctcaa tatttaaaac tttaaaaaaa tgttagtggt tgtaagcac 240
caatcttaac tatctcacct gcccgggcgg ccgctcgagg

40 <210> 16
<211> 2041
<212> DNA
<213> Human

<400> 16

45 cccccgcag aactcccccc tgggaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagagggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
50 atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taccaaaatt aacgcagctt aattagggac 480
caggtacata ttttctctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaatttttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
55 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaga 660
tagatatttg ttatagtctg acatttttaac agtcatagta ttagacgttt cgtgaccagt 720
gcatttttga ctctctcagg atcaaaaatac gagtctgcca actgtattaa atcctcctcc 780
acccctcca ccagttggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900
60 ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200
65 gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctgggtgtac atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

	taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
	catcagtgccc	tgaaggcttt	aatttttttag	caagggttctc	actaagatca	gtgaagtcaa	1440
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
	ccaaaaccag	tggccagtga	tacattgtct	aaaattttcc	ttctcacatg	atacttctga	1560
5	tcatatgaaa	atctcaggag	agtaagaata	aggtattcag	gttcctccgt	gatttgcata	1620
	gttttctcag	catttttgag	agaggcacag	ttttcacaat	aatattgggt	atcaccagta	1680
	agaatctctg	gagcccaaaa	aataatttag	taagtcagtt	actgaagggtg	tggtttcacc	1740
	tcccggtttc	tgagggtacat	ctttattaac	aagaatcttg	ttagattcgt	tagggacaga	1800
	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atgggttttt	cattcacaaag	1860
10	tgagtcacag	atgaaggcag	ctgttggttg	attataaact	actggctctt	ctgaaggacc	1920
	gggtacagac	gcttgcatga	gaccaccatc	ttgtatactg	gggtgatgatg	ctggatcttg	1980
	gacagacatg	ttttccaaag	aagaggaagc	acaaaacgca	agcgaaagat	ctgtaaaggc	2040
	t						
15	<210> 17						
	<211> 235						
	<212> DNA						
	<213> Human						
20	<400> 17						
	cgccccgggc	agggtgtcagg	ggttcctaac	cagcctgggg	aaacacagcg	tagacccttc	60
	acctctacaa	ataaaaaatt	aaaaaattag	ccagggtgtg	cagcgaaaca	ctgtagtctc	120
	agatactcag	gagactgagc	tggaaaggat	cacttgagcc	caagaagttc	aagggttacag	180
25	tggggccacga	tcatgttcatt	acactccagc	ttgggtgaca	aaatgagact	gtcta	
	<210> 18						
	<211> 2732						
	<212> DNA						
30	<213> Human						
	<400> 18						
	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttgcctggct	60
35	tcatgttgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120
	aaatattatc	ttcttggtga	tcacattgtg	caaaatgggt	aagcattcaa	acactttgaa	180
	accagattct	agcagggttg	aaaacattaa	gtcttggttg	cttggcgctt	tcgctcttct	240
	gtgtcttctt	ggcctcacct	ggtccttttg	gttgcctttt	attaatgagg	agactattgt	300
	gatggcatat	ctcttcacta	tatttaatgc	tttccaggga	gtgttcattt	tcactcttca	360
40	ctgtgctctc	caaaagaaaag	tacgaaaaga	atatggcaag	tgcttcagac	actcatactg	420
	ctgtggaggc	ctccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480
	cagtgtctcg	tattcctctg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540
	gagaaacaaa	tcagaatctt	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600
	tcaaggtggc	ataaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660
45	catcttcaag	atttatatca	tttagaggac	attcactgaa	caatgccagg	gatacaagt	720
	ccatggatac	tctaccgcta	aatggtaatt	ttaacaacag	ctactcgctg	cacaaggggtg	780
	actataatga	cagcgtgcaa	gttgtggact	gtggactaag	tctgaatgat	actgcttttg	840
	agaaaatgat	catttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900
	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
50	ctattgtggc	agatgcttca	tctttaatgc	acagcgacaa	cccagggtcg	gagctccatc	1020
	acaaagaact	cgaggcacca	cttattcctc	agcggactca	ctcccttctg	taccaacccc	1080
	agaagaaagt	gaagtccgag	ggaactgaca	gctatgtctc	ccaactgaca	gcagagggtg	1140
	aagatcacct	acagtccccc	aacagagact	ctctttatac	aagcatgccc	aatcttagag	1200
	actctcccta	tccggagagc	agccctgaca	tggagaaga	cctctctccc	tccaggagga	1260
55	gtgagaatga	ggacattttac	tataaaagca	tgccaaatct	tggagctggc	catcagcttc	1320
	agatgtgcta	ccagatcagc	aggggcaata	gtgatggtta	tataatcccc	attaacaaag	1380
	aagggtgtat	tccagaagga	gatgttagag	aaggacaaat	gcagctgggt	acaagtcttt	1440
	aatcatacag	ttaaggaatt	ccaaggcca	catgagagta	ttaataaata	aagacaccat	1500
	tggcctgacg	cagctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtggttctc	1560
60	tgggtgtaaaa	aagatgactg	aaccttgacg	ttctgtgaat	ttttataaaa	catataaaaa	1620
	ctttgtatat	acacagagta	tactaaagtg	aattatttgt	tacaaaagaa	agagatgcca	1680
	gccaggtatt	ttaagattct	gctgctgttt	agagaaattg	tgaatacaagc	aaaacaaaac	1740
	tttccagcca	ttttactgca	gcagtctgtg	aactaaattt	gtaaatatgg	ctgcaccatt	1800
	tttgtaggcc	tgcattgtat	tatatacaag	acgtaggctt	taaaatcctg	tgggacaaat	1860
65	ttactgtacc	ttactattcc	tgacaagact	tggaaaagca	ggagagatat	tctgcatcag	1920
	tttgcagttc	actgcaaate	ttttacatta	aggcaaagat	tgaataacatg	cttaaccact	1980

	agcaatcaag	ccacaggcct	tatttcatat	gtttcctcaa	ctgtacaatg	aactattctc	2040
	atgaaaaatg	gctaaagaaa	ttatatatttg	ttctattgct	agggtaaaat	aaatacattt	2100
	gtgtccaact	gaaatataat	tgatcattaaa	ataattttta	agagtgaaga	aaatattgtg	2160
	aaaagctctt	ggttgcacat	gttatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
5	ctactcattt	tcacttcttt	tccactgtat	acagtgttct	gctttgacaa	agttagtctt	2280
	tattactttac	attttaaattt	cttattgcca	aaagaacgtg	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgat	gaaatctaga	aaagattgtg	2400
	tgacacccct	gtttattctt	gaacagaggg	caaagagggc	actgggcact	tctcacaaac	2460
	tttctagtga	acaaaagggtg	cctattcttt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
10	actcttccat	attccttctg	cctatattta	gtaattaatt	tattttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttaataatga	gccccact	aatatccagt	gtaaagttta	acacggtttg	acagtaaata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210> 19						
	<211> 276						
	<212> DNA						
	<213> Human						
20	<400> 19						
	ctccctaaat	gatttttaaaa	taaattggat	aaacatatga	tataaagtgg	gtacttttaga	60
	aaccgccttt	gcatattttt	tatgtacaaa	tctttgtata	caattccgat	gttccttata	120
	tattccctat	atagcaaacc	aaaaccagga	cctcccaact	gcatgcctca	agtccctgtg	180
25	gagcactctg	gcaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaatacctcg	gccgcgacca	cgctgg			
	<210> 20						
	<211> 2361						
30	<212> DNA						
	<213> Human						
	<400> 20						
35	attgtaccag	ccttgatgaa	cgtgggccc	gcttcgcttt	tgaggggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccgta	ccggaagggt	tctcccaagt	120
	cagagtttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	tgtgcaacaa	gttcatagcc	tatagcaccg	tctttgagga	tgtagtggat	gtgcttgctg	240
	agtgggggct	cctgtacgtg	ctgacgcggg	atgggcgggt	ccacgcactg	caggagaagg	300
40	acacacagac	caaactggag	atgctgttta	agaagaacct	atttgagatg	gcgattaacc	360
	ttgccaaag	ccagcatctg	gacagtgatg	ggctggccca	gattttcatg	cagtatggag	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatatatc	cgaaccattg	480
	gaaagtgtga	gccatcctac	gtgatccgca	agtttctgga	tgcccagcgc	attcacaacc	540
	tgactgccta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccaccc	600
45	tgctcctcaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaagtc	cactttgatg	tggagacagc	catcaagggt	ctccggcagg	720
	ctggctacta	ctcccatgcc	ctgtatctgg	cggagaacca	tgacatcat	gagtggtagc	780
	tgaagatcca	gctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggcaagc	840
	tgccctttga	gcaggcagag	agcaacatga	agcgctacgg	caagatcctc	atgcaccaca	900
50	taccagagca	gacaactcag	ttgctgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgcag	cgatagggtg	gccccaggct	gcagggccaa	ctctgaggag	ttcatcccca	1020
	tctttgccaa	taaccgcgca	gagctgaaag	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tccttgagct	gcgactgcag	aactggggcc	1140
	acgagaagga	ttccacaggtc	aaagagaagc	ttcacgcaga	ggccatttcc	ctgctgaaga	1200
55	gtggctcgct	ctgcgacgtc	tttgacaagg	ccctggctct	gtgccagatg	cacgacttcc	1260
	aggatggtgt	cctttacctt	tatgagcagg	ggaagctggt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgagcagtag	cggcagggtc	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	accctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
	agtatgtggc	agctgtcctc	aagcatatcg	agaacaagaa	cctcatgccca	cctcttctag	1500
60	tggtgcagac	cctggccccc	aactccacag	ccacactctc	cgctcatcagg	gactacctgg	1560
	tccaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggt	1620
	accgagagga	gaccaccctg	atccgcagg	agatccaaga	gctcaaggcc	agtcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgctt	ggagttgccc	tcagtccact	1740
	tctgtgtgtg	ccactccttc	caccaacact	gctttgagag	ttactcgga	agtgtgctg	1800
65	actgccccac	ctgcctccct	gaaaaccgga	aggtcatgga	tatgatccgg	gcccagggaac	1860
	agaaacgaga	tctccatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

ctgtgattgc tgactacttt ggcagaggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggctgggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 agaacagaca caatgggacc tgggcgggcg ttacacagaa ggctggctga catgcccagg 2160
 5 gctccactct catctaattgt cacagccctc acaagactaa agcggaaactt tttcttttcc 2220
 ctggccttcc ttaattttta gtcaagcttg gcaatccctt cctctttaac taggcagggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340
 ttggaaaaaa aagctggttt c

10 <210> 21
 <211> 179
 <212> DNA
 <213> Human

15 <400> 21

aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60
 acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120
 20 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

<210> 22
 <211> 905
 <212> DNA
 <213> Human

25 <400> 22

30 tttttttttt ttctttaacc gtgtgggtctt tatttcagtg ccagtgttac agatacaaca 60
 caaatgttcc agttagaaagg aattcaaacg gaatgccaag gtccaagcca ggctcaagaa 120
 ataaaaaggg aggtttggag taatagataa gatgactcca atactactc ttcctaaggg 180
 caaagggtact tttgatacag agtctgatct ttgaaactgg tgaactctc ttcacccat 240
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtggtgggaa 300
 tagggctcatt aataactatg aatatactct ttagaagggtg accattttgc actttaaagg 360
 gaatcaattt tgaaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 35 gggagctgga agagccttgg aagtttctat tacaatatga gcaccatatt cttcatgcca 480
 aatctcaaca aaagctcttt ttaactccat ctgtccagtg tttacaaata aactcgcaag 540
 gtctgaccag ttcttggtta caaacatata tgtgtgtgtc tgtgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc tttcaaacat tgggggaacc agtagaaaaa 660
 ggcagggtc cctaattgtcc attattacat ttccattccg aatgccagat gttaaaagt 720
 40 cctgaagatg gtaaccagc tagtgaggaa taaatacccc acctgcccc gtccacagag 780
 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagttag tgttttttcg 840
 ccatggattg cagtcctctc ctccagacca gctgcttatt tcctcagggg ccaggggaat 900
 gttga

45 <210> 23
 <211> 2134
 <212> DNA
 <213> Human

50 <400> 23

55 ggtctcttct ttctttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60
 gtataaatac tctattttat atgcacttcc acaaaaagcga tataatttaa aagttttttt 120
 cattagaaat aaatgtataa aaataaatat gttattatag gcatttatta ctaactatag 180
 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300
 accaggatac gactgttgga ccagctgctg gagatggacc tgctaccct cagcagcctc 360
 cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420
 tcatttttgt tccggcggtt catcctcctt gtgtgattgt actgattttc atgagacaca 480
 60 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaagt 540
 tggagggtact aagctcattg tgtctcctct agcttttacc agcatctaatt gcttactgc 600
 tttttttcca ttgtagactt taatgcactt gaataaatat atggagttgt ttttctccta 660
 aaatgaatta cacaataaaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720
 gttattttcac gttgctgagc cttctcttca tgttgaaaca tctgaagttt taattctcgg 780
 65 tagaaataat gtataaacat tctctgaaac catagcagcc ataaacagtg ctggtcaaag 840
 atcctatttg tactcctttc tccccccatt gttagtgagg taaagtaaaa cagggtcttag 900

5 taaaatctca cttttctcct acttttctatt tcccaacccc catgatacta agtattttgat 960
 aagtaccagg aaacaggggt tgtaatatgt ctaacttttt ttgacaattg ctttggtttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccg ggctttatta 1080
 tgctatatca ctgctcagag gttaataatc ctactaact atcctatcaa atttgcaact 1140
 ggcagtttac tctgatgatt caactccttt tctatctacc ccataatcc caccttactg 1200
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgccttccct 1260
 gcaccagccc ttctcactt tgccctggcc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa agtctatga aatgtttagg tttctttaa ggatcacagc 1380
 tctcatgaga taacaccctt ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 10 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 ggtctgcaca aggtctggtg ctggctggct tcaacttctt tgcacactcg gaagcaggct 1560
 gtccattaat gtctcgcat tctaccagtc tctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcaaggggca ttgccacag 1740
 15 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgtgttac ctcaagacaa cacttttgta cataatgtct tgctctaag 1860
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gtctctggat cccctctggt tccgctgttt cacttcgatg ttggtggctc 1980
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040
 20 tttttttaca agtagatcca ttccccgc aaacaccaca tttatcaaac ttctttttgg 2100
 agtctatgat gcgatcacia ccagctttta caca

<210> 24

<211> 1626

25 <212> DNA

<213> Human

<400> 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgccttaaaa tatattttgg 60
 ttattttgaa tacagacatt ggctccaaat ttcatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gtttaaggctg 180
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacagggt gaacaaacgt 240
 agttgttttt tactgatact aaatgtttggc tacctgtgat tttatagtat gcacatgtca 300
 35 gaaaaaggca agacaaatgg cctcttgtag tgaatacttc ggcaaaactta ttgggtcttc 360
 atttctgac agacaggatt tgactcaata tttgtagagc ttgcgtagaa tggattacat 420
 ggtagtgatg cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggttttag 540
 aaagctttgt ctaaaaattt ggcctaggaa tggttaactt attttcagtt gccaaagggt 600
 40 agaaaaataa tatgtgtgtt gttatgttta tgtaacata ttattaggta ctatctatga 660
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaac tcagggttacc cttgaaggat atgctggcag 780
 ccatctcttt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttga 840
 tctggaatgc attagttatg ccttgtagca ttcccagaat ttcaggggca tctggtgggtt 900
 45 ggtcctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atcctaacta actggctctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 50 aactaagata ttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200
 cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctgttac tgcaatcaca 1320
 atgccagatg gtgtttatgg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380
 tgtgtttgtt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440
 55 tgggtcaata tggatgcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500
 attatacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatatat 1560
 tacttgaaaa tattttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa

<210> 25

60 <211> 1420

<212> DNA

<213> Human

<400> 25

65 gtccagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60

5 ggtgaactca gtgcattggg ccaatggttc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggtttggc tgctgggtgg ctttcccttc actgtcattg gaggcattct 120
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccgga 180
 gattccaccc cagccctggt acaagtctac tgtcatccac atgactgttg gaggcttcct 240
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgcaactca cctacttcca gttgtctggg gaggattacc gctgggtggg 420
 10 gcgatctgtg ctgagtgttg gctccaccgg cctcttcac ttcctctact cagttttcta 480
 ttatgcccg cgctccaaca tgtctggggc agtacagaca gtagagttct tcggctactc 540
 cttactcaact gggttatgtct tcttcctcat gctgggcacc atctcctttt tttcttcct 600
 aaagtctatc cgggtatatct atgttaacct caagatggac tgagttctgt atggcagaac 660
 tattgtctgt ctctcccttt cttcatgccc tgttgaactc tcctaccagc ttctcttctg 720
 attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780
 15 ccagagaggg cctggaaatt ataaatctct atcacataag gattatataat ttgaactttt 840
 taagttgcct ttagttttgg tcctgatttt tctttttaca attacccaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

<210> 29
 <211> 1775
 <212> DNA
 <213> Human

25 <400> 29

30 gaacgtgatg ggaacttttg gaggatgtct gagaaaatgt ccgaagggat tttggccaac 60
 accagaaaac gccaatgtcc taggaattcc ctcccaaat gcttcccaaa aaattactca 120
 ttgacaattc aaattgcact tggctggcgg cagcccgggc ggccttcagt ccgtgtgggg 180
 cgcccgctg gccttctcct cgtaggactc cccaaactcg ttcactctgc gtttatccac 240
 aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccggtga gacgtgggca tgggtgatgat gaaggcaaa acgtcatcaa tgaagggtgt 360
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca acttgtagtt 420
 cacaagagc tggggcagca tgaagaggaa accaaaggca tagaccccg tgaagagct 480
 35 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 ccgacacag agaggggtaca gcaggtatga caagtacttc atggcctgag tatcgtactc 600
 ctgggttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcatcttca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 40 ctcggtgctg aagcagcgcc agagcactgc cttgggtggac atgccgatca tgctcttctt 840
 cttcttccag aaactgatgt cattttttaa ggcagggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaag aaggtcagcg ccaggaagta taagttggta tctacaaaaa ttcctttcac 960
 ctcatcagca tctttctctg aaaacccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020
 gtggatccag aagcgcagcc gccccagtga gaccttctcg taggacacgg tgaggggag 1080
 45 ctcggtgggt gagcggttta tgaccatcag gtccttcaac cggttgctga gctggtcgat 1140
 gaacaggatg ggcaggtaat gcacggtttt ccccagctgg atcatcttca tgtaccgatg 1200
 cacatcgcca ggcagggagg acccgtcaaa gacaaagtgt tccgccatca cgttcagcgc 1260
 cagccgcggt cgccagtggg aactggctc atccagggca ctcgctcggt tcttctccgc 1320
 ctcgatctgc tgtgtatcag actccccggt gagcagggtt atttcttctg gcttggggac 1380
 catgtagggt gtcagaggac tgaccagggt cacctgcttc ccgtcgtgcc acggcaggac 1440
 50 cccagcgtga tggaggaaga tgtaggcata cagcgtccca ttgtttctcg ttttctttgg 1500
 tacagaaaca ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggtcg atgtgttct cagcaccacg gtgggacctc gtcgtgggtg acacgctcag 1620
 ctgcagcttg ggcgcgcg cgaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680
 55 cgggtgtag acgatgccgt acatgacca gcaggtgtgc accacgtaga ccacgaacac 1740
 gccaccacc aagctggtga aggagctgcg gcccc

<210> 30
 <211> 1546
 <212> DNA
 <213> Human

60 <400> 30

65 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgcta 60
 aaggccctgc caggctggga ggaattgtc cctgcctgct tctggagaaa gaagatattg 120

	acaccatcta	cgggcaccat	ggaactgctt	caagtgacca	ttctttttct	tctgccag	180
	atttgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacacaaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
5	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaag	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaa	540
	acagaaatac	caggtagtgt	tctacaacca	gatgcatcac	cttctaaaac	tggtacatta	600
	acctcaatac	cagttacaat	tccagaaaac	acctcacagt	ctcaagtaat	aggcactgag	660
10	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccg	720
	gtggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	tttgtagcga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
15	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccagct	tccataacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcggt	cctaggaaaa	ggaattttag	1200
	gaggagaatt	tgtagcagat	gaatctgaca	gcccagggag	tggtctcgct	gataggcatg	1260
20	actttcctta	atgtttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tgttcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgcacgtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
	gtacatatata	gtattttatt	cctgctttcg	tgttactttt	aataaataac	tactgtactc	1500
25	aatactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		
	<210>	31					
	<211>	750					
	<212>	DNA					
	<213>	Human					
30							
	<400>	31					
	cacttgggca	ccccattttt	ctaaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
	aagggaagtg	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
35	atagcaaatg	gattcctttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	cccactaaag	cagaacgtta	cggatatatt	tggttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgttttaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacata	360
	cagtgaaca	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
40	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagttatag	480
	ttttaatagc	ttcctcagca	cactatttcc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccata	ggctcttgta	aaaggaagtc	tgaatacaga	gcccacaaca	ctaaaattgt	600
	ttttctagct	acaaagtata	gcacatcaaa	cacagacacg	atttggactc	cctgacaggt	660
	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
45	ccaaaggcct	tatttgtcac	caccgtcccg				
	<210>	32					
	<211>	1620					
	<212>	DNA					
50	<213>	Human					
	<400>	32					
	gcaattcccc	cctcccaacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
55	gtgcagccat	tcataagaac	cttgggtgccc	cagaaaaatc	tgctcctttt	ggtaccaaac	120
	ctgagggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggcta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggatcc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
	atgttctggg	ttttttcctt	cttttttagaa	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
60	aaaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcactta	ttccaggaca	420
	cgctggcatt	tggactcaat	gaaaagggca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	tccataattt	tcacacaata	acagtcctct	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgcccctc	cccttggttt	tcaagtatct	660
65	tggagttgtg	cacaaaaaatt	aggtcatgcc	ttcagtgctc	tgttctttaa	acctaccctt	720
	tgacaatcag	gtgctaataga	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

5 gtgttcctcc taggttgga gaaatgtctt tccttctatc tgggtcctgt taaagcgggt 840
 gtcagttgtg tcttttcacc tcgatttgtg aattaataga attgggggga gaggaaatga 900
 tgatgtcaat taagtttcag gtttgcatg atcatcattc tcgatgat tctcactttg 960
 tcgcaaatct gcccttatcg taagaacaag ttccagaatt ttccctccac tatacgactc 1020
 cagattatg tttacaatcc attggatgag tgcagcatta taagaccttg gtgccagaa 1080
 aaatctgtcc tttttgttac caaacctgag gtcttttggga agataatgta gaaaaccact 1140
 acctattgaa ggctgtttt ggctaactct tgcaaaactct gatgatacct gcttatgtgg 1200
 attcttttcc acactgcttt ctttttaag tataaagact tagaaaacta gaataatgct 1260
 10 tttacaaata attaaaagta tgtgatgttc tgggtttttt ctttctttt agaaccctgt 1320
 atttaaacaa gccttctttt taagtcttgt ttgaaattta agtctcagat cttctggata 1380
 ccaaatcaaa aaccacaacgc gtaaaacagg gcagttattg tgttcctaata tttaaaaaagc 1440
 tttatgtata ctctataaat atagatgcac aaacaacact tccccttgag tagcacatca 1500
 acatacagca ttgtacatta caatgaaat gtgtaactta aggggtattat atatataaat 1560
 15 acatatatac ctttgaacc tttatactgt aaataaaaaa gttgctttag tcaaaaaaaa 1620

<210> 33
 <211> 2968
 <212> DNA
 <213> Human

20 <400> 33

25 gaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaaccctga agaggaggag 60
 gaggaggaag aagaggaaga agaagatgaa gaaagtgaag aggaggagga agaggaggga 120
 gaaagtgaag gcagtgaagg tgatgaggaa gatgaaaagg tgcagatga gaaggattca 180
 gggaagacat tagataaaaa gccaaagtaa gaaatgagct cagattctga atatgactct 240
 gatgatgatc ggactaaaga agaaagggct tatgacaaag caaaacggag gattgagaaa 300
 cggcgacttg aacatagtaa aaatgtaaac accgaaaagc taagagcccc tattatctgc 360
 30 gtacttgggc atgtggacac agggaagaca aaaattctag ataagctccg tcacacacat 420
 gtacaagatg gtgaagcagg tggatcacca caacaaattg gggccaccaaa tgttcctctt 480
 gaagctatta atgaacagac taagatgatt aaaaattttg atagagagaa tgtacggatt 540
 ccaggaaatgc taattattga tactcctggg catgaatctt tcagtaatct gagaaataga 600
 ggaagctctc tttgtgacat tgccatttta gttgttgata ttatgcatgg tttggagccc 660
 35 cagacaattg agtctatcaa ctttctcaaa tctaaaaaat gtcccttcat tgttgactc 720
 aataagattg ataggttata tgattgaaa aagagtcctg actctgatgt ggctgctact 780
 ttaagaagc agaaaaagaa tacaaaagat gaatttgagg agcgagcaaa ggctattatt 840
 gtagaatttg cacagcaggg tttgaatgct gctttgtttt atgagaataa agatccccgc 900
 acttttgtgt ctttggtaac tactctgca catactgggt atggcatggg aagtctgac 960
 40 tacttcttg tagagttaac tcagaccatg ttgagcaaga gacttgcaaa ctgtgaagag 1020
 ctgagagcac aggtgatgga ggtaaaagct ctcccgggga tgggcaccac tatagatgtc 1080
 atcttgatca atgggcgttt gaaggaagga gatacaatca ttgttcctgg agtagaagg 1140
 ccattgttaa ctacagattc aggcctcctg ttacctcctc ctatgaagga attacgagtg 1200
 aagaaccagt atgaaaagca taaagaagta gaagcagctc aggggggtaaa gattcttgga 1260
 45 aaagacctgg agaaaacatt ggctggttta cccctccttg tggcttataa agaagatgaa 1320
 atccctgttc ttaaagatga attgatecat gagttaaaag agacactaaa tgctatcaaa 1380
 ttagaagaaa aaggagtcta tgtccaggca tctacactgg gttctttgga agctctactg 1440
 gaatttctga aaacatcaga agtgccttat gcaggaatta acattggccc agtgcataaa 1500
 aaagatgta tgaaggcttc agtgatgttg gaacatgacc ctgagtatgc agtaattttg 1560
 50 gccttcgatg tgagaattga acgagatgca caagaaatgg ctgatagttt aggagttaga 1620
 attttttagtg cagaatttat ttatcattta tttgatgcct ttacaaaata tagacaagac 1680
 tacaagaaac agaaacaaga agaatttaag cacatagcag tatttccctg caagataaaa 1740
 atcctccctc agtacatttt taattctcga gatccgatag tgatgggggt gacgggtgaa 1800
 gcaggtcagg gacacccatg gacaccccaa tgtgtcccaa gcaaaaattt tgttgacatc 1860
 55 ggaatagtaa caagtattga aataaaccat aaacaagtgg atgttgcaaa aaaaggacaa 1920
 gaagtttggtg taaaaataga acctatccct ggtgagtcac ccaaaatggt tggagacat 1980
 tttgaagcta cagatattct ttttagtaag atcagccggc agtccattga tgcactcaa 2040
 gactggttca gagatgaaat gcagaagagt gactggcagc ttattgtgga gctgaagaa 2100
 gtatttgaaa tcatctaatt ttttcacatg gagcaggaac tggagttaaa gcaatactgt 2160
 60 gttgtaatat cccaacaaaa atcagacaaa aaatggaaca gacgtatttg gacactgatg 2220
 gacttaagta tggaaaggaag aaaaataggt gtataaaatg ttttccatga gaaaccaaga 2280
 aacttacact ggtttgacag tggtcagtta catgtcccca cagttccaat gtgcctgttc 2340
 acctacctct cccttcccca acccttctct acttggctgc tgttttaaaag tttgcccctc 2400
 65 cccaaatttg gatttttatt acagatctaa agctctttcg attttatact gattaaatca 2460
 gtactgcagt atttgattaa aaaaaaaaaa gcagattttg tgattcttgg gacttttttg 2520
 acgtaagaaa tacttcttta tttatgcata ttcttccac agtgattttt ccagcattct 2580
 tctgccatat gcctttaggg cttttataaa atagaaaatt aggcattctg atatttcttt 2640

agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
 agtcacagagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaaacaga 2760
 catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
 5 ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940
 tgatcggttt agtagagatt ttatacat

<210> 34

<211> 6011

10 <212> DNA

<213> Human

<400> 34

15

acggggcgcc ggacgacccg cacatcttat cctccacgcc ccaactcgac tcggagcggy 60
 accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgcccggc 120
 20 cggcttgagc agagcgcagc acccccgcgc ccccgcgcca gaagtttggt tgaaccgggc 180
 tgcggggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240
 ggaactcccc cgccccaaag ctctgtgggt cggggtcgcg cggccgcaga aggggcccgg 300
 tccgcccgcg aggggagggc cccccgggga cccgagaggg gggtagaggac cgcgggctgc 360
 tgggtcggcg gcggcagcgt gtgccccgcg caggggaggg gccgccccgc tcccggcccc 420
 25 gctgcgagga ggaggcggcg gcggcgaggg aggatgtact tgggtggcggg ggacaggggg 480
 ttggcgggct gcgggcacct cctggctctg ctgctggggc tgctgtctgt gccggcgcg 540
 tccggcaccc gggcgctggt ctgcctgccc tgtgacgagt ccaagtgcga ggagcccagg 600
 aaccgcccgg ggagcatcgt gcagggcgct tgcggctgct gctacacgtg gccagccag 660
 gggaacgaga gctgcggcgg caccttcggg atttacggaa cctgcgaccg ggggctgctg 720
 30 tgtgtcatcc gccccccgct caatggcgac tccctcaccg agtacgaagc ggcggtttgc 780
 gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
 aatccctttg agtttccaag tcaggatatg tgcccttcag ctttaaagag aattgaagaa 960
 35 gagaagccag attgctccaa gggccgctgt gaagtccagt tctctccacg ttgtcctgaa 1020
 gattctgttc tgatcgaggg ttatgctcct cctggggagt gctgtcccct acccagccgc 1080
 tgcgtgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtgt acctctatga gtgcaacca 1200
 gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
 cgggacagct atgaaactca agtcagacta actgcagatg gttgctgtac ttgccaaca 1320
 40 agatgcaggt gtctctctgg cttatgtggg tttcccgtgt gtgaggtggg atccactccc 1380
 cgcatagtct ctctgtggca tgggacacct ggaaagtgt gtgatgtctt tgaatgtgtt 1440
 aatgatataa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcg 1560
 45 cagtgtgggt agataaactg cgagaggtac tacgtgcccc aaggagagtg ctgccagtg 1620
 tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgcaa tggcctgatc 1680
 cttgccccag gagaccgggt gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagtgtatcc acctgcatgt 1860
 50 cacaatgggt gtcggacctg tcagtgcata aacaccagg aactatgttc agaacgtaaa 1980
 caaggctgca ccttgaactg tcccttcggt ttccttactg atgccccaaa ctgtgagatc 2040
 tgtgagtgcc gcccagggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
 cttggattgc tgaagaataa gcacggctgt gcacatctgt cgtgtaagaa atgtccagag 2160
 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttata 2220
 55 tgcaagtgca gagaggcctc tgcttcagct gggccacca tcctgtcggg cacttgtctc 2280
 accgtggtat gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
 tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgctgtgccc 2400
 aaccccacca ttcaccctgg acagtgtgc ccatcatgtg cagatgactt tgtggtgcag 2460
 aagccagagc tcagtactcc ctccatttgc cagccccctg gaggagaata ctttgtggaa 2520
 60 ggagaaacgt ggaacattga ctctgtact cagtgcacct gccacagcgg acgggtgctg 2580
 tgtgagacag aggtgtgccc accgctgtct tgccagaacc cctcacgcac ccaggattcc 2640
 tctgcccac agtgtacaga tcaacctttt cggccttctc tgtcccga taacagccta 2700
 cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
 65 gacgtttgta ccagctgcat ctgcattgat agcgttaatta gctgtttctc tgagtctctc 2820
 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgtgtgcc ctactgcata 2880
 aaagacacaa ttccaaagaa ggtgggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

	gagcgggtggg	accttgacag	ctgcacccac	tgctactgcc	tgcaggggcca	gaccctctgc	3000
	tcgaccgtca	gctgcccccc	tctgcccgtg	gttgagccca	tcaacgtgga	aggaagtgtg	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
	aaccatcgag	gagagggttg	cctggaggtt	cccctgtggc	ccacgcctag	tgaaaatgat	3180
5	atcgtccatc	tccttagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	caccaagtg	aagattcttc	actggactcc	attgctcag	ttgtggttcc	cataattata	3300
	tgccctctcta	ttataatagc	attcctattc	atcaatcaga	agaaacagt	gataccactg	3360
	ctttgtctgt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
	gactgcaaga	aaggaaccag	agtccagggtg	gacagtcccc	agagaatgct	aagaattgca	3480
10	gaaccagatg	caagattcag	tggcttctac	agcatgcaaa	aacagaacca	tctacaggca	3540
	gacaatttct	accaaaccag	gtgaagaaa	ggaactagga	tgaggtttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaaact	agaatttgtg	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
	atgtgcagaa	caagcattcc	cacttttctc	caagataact	gaccaagtgt	tttcttagaa	3780
15	ccaaagtgtt	taaagtgtct	aagatatatt	tgctgtgaag	atagctgtag	agatatattg	3840
	ggtggggaca	gtgagtttgg	atggggaaa	gggtgggagg	gtggtgttgg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggt	aacataaaa	cagttcagtg	gcccagagg	3960
	tatttttttc	ctattgctct	gaagactgca	ctggttctg	caaagctcag	gcctgaatga	4020
	gcaggaaaca	aaaaaggcct	tgccgacccag	ctgccataac	caccttagaa	ctaccagacg	4080
20	agcacatcag	aaccttttga	cagccatccc	aggtctaaag	ccacaagtgt	cttttctata	4140
	cagtcacaac	tgcatagggc	agtgaagaa	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttattt	tcttccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
	atgtgagcac	tggagctttt	tttttttaca	acgtgacagg	aagaggagg	agagggtgac	4380
25	gaacaccagg	catttccagg	ggctatatatt	cactgtttgt	tggtgctttg	ttctgttata	4440
	ttgttggttg	ttcatagttt	ttgttgaagc	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgttttg	ggattctttt	tccttattat	atactgattc	tacaaaatag	aaactacttc	4560
	attttaattg	tatatatttc	aagcaccttt	gttgaagctc	aaaaaaaatg	atgcctcttt	4620
	aaacttttag	aattatagga	gtatttatgt	aactatctta	tgcttcaaaa	aacaaaagta	4680
30	tttgtgtgca	tgtgtatata	atatatatat	atacatatat	atttatacac	atacaattta	4740
	tgttttcctg	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgtcttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggt	4980
35	attcctttat	taaaatcttc	ctcatttgga	tttgctttca	gttggttttc	aatttgctca	5040
	ctggccagag	acattgatgg	cagttcttat	ctgcactact	aatcagctcc	tggatttttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttgttg	tagtatgcct	caaataatac	tgactgtata	ctatagtgg	aacttttcaa	5220
	acagccctta	gcacttttat	actaattaac	ccatttgtgc	attgagtttt	cttttaaaaa	5280
40	tgcttgttgt	gaaagacaca	gataccagct	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaag	gaactttcaa	gtattgttgt	aaatacttgg	acagagggtg	ctgaacttta	5400
	aaaaaaatta	atttattatt	ataatgacct	aatttattaa	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aagggtgttc	agctgtttgc	atcaaaggaa	5520
	aaaaagattt	attatcaagg	ggcaatatatt	ttatcttttc	caaaataaat	ttgttaatga	5580
45	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	cattcctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	ttgttttttt	5700
	caatcatggc	catattatga	aaatactaac	aggatatagg	acaagggtga	aattttttta	5760
	ttattatttt	aaagatatga	ttatctctga	gtgctgtatc	tattactctt	ttacttttgt	5820
	tcctgtttgt	ctcttgtaaa	agaaaaatat	aatttcctga	agaataaaat	agatatatgg	5880
50	cacttgaggt	gcacataggt	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaaa	a					
55	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
60	<400>	34a					
	mylvagdrgl	agcghllvsl	lgllllpars	gtralvclpc	deskceprn	rpgsivqgvc	60
	gccytcasgg	nescgggtfgi	ygtcdrglrc	virpplngds	lteyeagvce	denwtdqll	120
65	gfkpcnenli	agcniingkc	ecntirtcsn	pfefpsqdmc	lsalkrieee	kpdcskarce	180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpge	240

5 ccdlyeckpv fgvdcrvec ptvqqtacpp dsyetqvrllt adgcctlptr ceclsglclgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmfr mdncrfrcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcwatvcgq tctnpvkvpq eccpvcept iitvdppacg elsnctltrk 480
 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfqf ltdaqnceic ecrprpkkr 540
 piicdkycpl gllknkhgdc icrckkcpel scskicplgf qqdshgcllc kreasasag 600
 ppilsgtclt vdghhkhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfvge etwnidsctq ctchsgrvlc etevcppllc 720
 10 qnpsrtqdsq cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkpd vctscicids 780
 viscfesescp svscerpvlr kgqccpycik dtipkkvch fsgkayadee rwdldscethc 840
 yclqgqtlcs tvscpplpcv epinvegsc pncpemyvpe ptnipiektn hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiic lsiiiaflfi 960
 nqkkqwipll cwyrtptkps slnnqlvsdv ckkgrtrvqd ssqrmlriae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35

<211> 716

<212> DNA

20 <213> Human

<400> 35

25 gcagtacctg gagtgtcctg caggggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctggggccgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtccag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180
 ggaggtctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 30 ccagaactcg gtcctatattt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgaggggaat ctctcgattc tccttatatg acctcaaaact gaccatacta aacagtgtag 360
 aaggtctttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgatca 420
 gtcagtgtgg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggg cttaagacc ccaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 tctggttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600
 35 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36

<211> 395

40 <212> DNA

<213> Human

<400> 36

45 ccaatacttc atttctcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaaa 180
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
 gcccagtaaa accaaagtca gggtaaccaa tgtcatttta caaaatgtta aaacccta 300
 50 tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37

<211> 134

55 <212> DNA

<213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaaa gctgcctggc tttcagcaac aggcctatca acaccatggg gactctccat 120
 aaggacacc gtgt

<210> 38

65 <211> 644

<212> DNA

<213> Human

<400> 38

```

5  aagcctgttg tcattggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
   cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
   gggaagagtg ccagtgagcg cactgttaca attcaagatc ttgatctata tccatagatt 180
   ggaatattgg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
   gcttgggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
10  ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaaga 360
   aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
   ttcgcaccgg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480
   caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
   tcaaaggcct ctttggaaaa actggaaaaga aagcagttta agcagtttct gtgggtctaa 600
15  gcagatggac tcagaggttg tggatgaaaa actaaggacc tcatt

```

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

```

25  ctttttgttt gggttttcca atgtagatgt ctcagtgaaa tgtgcagata tactttgttc 60
   cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggg tcctggccca 120
   gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
   tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
   acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
30  agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
   tggtcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
   ttttttgttt tttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480
   aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
   taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaataattag 600
35  atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

```

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

```

45  acaattttaa aataactagc aattaatcac agcatatcag gaaaaagtac acagtgagtt 60
   ctggttagtt tttgtaggct cattatgggt agggctcgta agatgtatat aagaacctac 120
   ctatcatgct gtatgtatca ctcattccat tttcatgttc catgcatact cgggcatcat 180
   gctaataatgt atccttttaa gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240
   ggtaaaaaaa attcccaaaa tattttgcac tgaatgtacc aaaggtgaag ggacattaca 300
   atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
50  acttccttca cagtggcgtg tctaccacta caaggactgt gcatctaagt aataattttt 420
   taagattcac tatatgtgat agtatgatat gcattttattt aaaatgcatt agactctctt 480
   ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
   gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600
   tgaagagatc atagtaaga attccatttt ccctcatcag tgaagacacc acaatttgaa 660
55  actcagaact atatttctaa gcctgcattt tcaactgatgc ataattttct tagtaatat 720
   aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
   ttaattttat gagaaggat tcttcatttt aattgctttt gggattactc cacatctttg 840
   tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900
   attggattga catatgggtt gccagcctat gggtttacag gcattgcccc aacatttctt 960
60  tgagatctat atttataagc agccatggaa ttcctattat gggatgttgg caatcttaca 1020
   ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
   gtgagttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140
   ctgactataa ggcacgtact gcagtgtagt gaaatgttct gaaaaagggg tatagaaatc 1200
   tggaaaataa aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
65  ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
   tgaaaaaa

```

<210> 41
 <211> 987
 <212> DNA
 <213> Human

5

<400> 41

```

aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60
tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120
10 taacccccgg ctatcagtcg ggaatggttc caccctccct gctgtaggat ggaagcagcc 180
atggagtggg agggaggcgc aataagacac cctccacag agcttggcat catgggaagc 240
tggtttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300
tgtctttctc ttctccaacc aacagaaaag actgctcttc aaaggtggag ggtcttcattg 360
aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420
15 ggaggaggga ggagctggta gggagatgct ggctttacct aaggtctcga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacgaaa 540
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
20 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatatcaa 780
aatagtctac ggccatacca ccctgaacgt gcctaattct gtaagctaag cagggtcagg 840
cctggttagt acctggatgg ggagagtatg gaaaacatac ctgccgcag ttggagttgg 900
actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960
tgaaagtagc atttggtgtg aaaaaaa

```

25

<210> 42
 <211> 956
 <212> DNA
 <213> Human

30

<400> 42

```

cggacgggtg ggcggacgcg tgggtgcagg agcagggcgg ctgccgactg cccaaccaa 60
ggaaggagcc cctgagtcg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
35 ttgcctgtct aaagccttaa ctaagactcc cgcccgggc tggccctgtg cagaccttac 180
tcaggggatg ttacctggt gctcgggaag ggaggggaag gggccgggga gggggcacgg 240
caggcgtgtg gcagccacac gcaggcggcc agggcggcca gggacccaaa gcaggatgac 300
cacgcacctc cagccactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360
tcgcagcccc cgcgccctcc ctccgcctcc catccgctt agcgtcttgg acagatggac 420
40 gcaggccctg tccagcccc agtgcgctcg ttccggtccc cacagactgc cccagccaac 480
gagattgtcg gaaaccaagt caggccaggt gggcggaaca aagggccagg tgcggcctgg 540
ggggaacgga tgctccgagg actggactgt tttttcaca catcgttggc gcagcgggtg 600
gaaggaaaag cagatgtaaa tgatgtgtt gtttacaggg tatattttt ataccttcaa 660
45 tgaattaaat cagatgtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720
tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780
tcgcaggacc aagggggcgg ggactgctgg ctcacgcccc gctgtgtcct ccctccctc 840
ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtggt 900
ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

```

50

<210> 43
 <211> 536
 <212> DNA
 <213> Human

55

<400> 43

```

aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
60 agtggttagt gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
tctaaataaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300
cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
attttttcca gatgaaactt gtgccacttc caattgacta atgaaataca aggagacaga 420
ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaatatta tggtagctaa 480
65 aggggtggtt ccccgccacc tggacctgga caggtagggg tccgtggtta accagt

```


<210> 44
 <211> 1630
 <212> DNA
 <213> Human

5

<400> 44

ggggaggggac gagtatggaa ccctgaaggt agcaagtcca ggcaactggcc tgaccatccg 60
 gctccctggg caccgaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
 10 tctattttta tcacaatgac cttagagag gtctcccagg ccagctcaag gtgtcccact 180
 atcccctctg gaggggaagag gcaggaaaat tctcccggg tccctgtcat gctactttct 240
 ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
 gtgatttccc ttaggccag gacttgggccc tccagctcat ctgttccttc tggggccatt 360
 catggcagggt tctgggtcca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
 15 gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
 tacttggttac gggaaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
 gacaggattg gctcagatga cccctgaggg ctcttcagg cttgaaatgc attccatgat 600
 attaggaagt cgggggtggg tgggtggtgg gggctagtgg ggtttgaatt tagggggccga 660
 tgagcttggg tacgtgagca ggggtgtaag ttaggggtctg cctgtatttc tgggtcccctt 720
 20 ggaaatgtcc ccttcttcag gtgcagacct cagtcccagt gtccatctcg tgcccagaaa 780
 agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctgg 840
 gccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttgggtggc 900
 tgtgattcag gtcccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
 gaggttggctg gtagagcctt ctgagggttc agaattattg cttcaggatc agctgggggt 1020
 25 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaaagg 1080
 tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa cccccaagt 1140
 aggtcggagg gagttaagg cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200
 aaagagtga cttagagggc tccttggggc tcaggaatgc tcctgtctgt gtgaagatga 1260
 gaagggtgctt ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgtct 1320
 30 ctgggtccct tgtagcacag gagactgggg ctaaggggccc ctcccaggga agggacacca 1380
 tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccagagg 1440
 actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgctct gctgttctct 1500
 cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
 35 cctcttgcct cttgtagaat gcagctctgg ccctcaataa atgcttctg cattcatctg 1620
 caaaaaaaaa

<210> 45
 <211> 169
 <212> DNA
 <213> Human

40

<400> 45

tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
 45 taaaactggg ttatgatctt cagtctgatt ccagtgtctg ataactagat aacgtatgaa 120
 ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaaga cttagttga

<210> 46
 <211> 769
 <212> DNA
 <213> Human

50

<400> 46

tgcaaggatc atttactatc ggcaataaaa ggaagcaaag cagtattaa cagcgggtgga 60
 55 atttgtcgct ttcacttttt ataaagtgtc acataaaatg tcatatttcc aaatttaaaa 120
 acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180
 aaacaaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataga 240
 aagggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300
 60 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
 ctcatataaa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
 ggcagctcc tttctgata gctctgattc gccttcatat ataggcagct cctgatcatc 480
 catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
 tattttgtaa taaaatcaaa tttccattg aaaccttcaa aaactttgca gaatgagggt 600
 65 ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
 cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47

<211> 2529

5 <212> DNA

<213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatac tttcacaaca 60
 gtgaaaatta gtgactggtt aaggtgtgcc actgtacata tcatcatttt ctgactgggg 120
 tcaggacctg gtcctagtcc acaagggttg caggaggagg gtggaggcta agaacacaga 180
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
 ggatgggtgg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
 15 gccttactta gctcctggca gaggtgagtg ggggacctac gaggttcaaa atcaaattggc 360
 atttggccag cctggcttta ctaacaggtt ccagagtgct ctctgttggc tgagctctcc 420
 tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540
 actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
 20 ccagaggccc ctgcaacttt gcggatttcc agaagtgat aaaaagagca ctcttgagtg 660
 ggtgccccag aatgttttaa atctatcagg cacactataa agctgggtgt ttcttcctac 720
 caagtggatt cggcatatga accacactact caatacttta tattttgtct gtttaaacac 780
 tgaactcttg tgttgacagg tacaaggag aagagatggg gactgtgaag aggggagggc 840
 ttccctcatc ttccctcaaga tctttgtttc cataaactat gcagtcataa ttgagaaaaa 900
 25 gcaatagatg gggcttccta ccatttgttg gttattgtcg gggtagcca ggagcagtg 960
 ggatggcaca gtaggagaga ggccagagg aaagccatc tccctccagc tttggggtct 1020
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
 aggtgaacag tcctacctgc ttgttaccat agtccctcaa taagattcag aggaagaagc 1140
 ttatgaaact gaaaatcaaa tcaaggattt gggaagaata atttccctc gattccacag 1200
 30 gaggggaagc cacaactat cattgtgctg gggctcccca aggcctgccc acctggcttt 1260
 acaaatcatc aggggttgcc tgcttgccag tcacatgctt ccctggtttt agcacacata 1320
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcat 1440
 35 gcagttgggg tgacctgaca aagcccccag tttcctgttg caggttcttg gagaggatgc 1500
 attcaagctt ctgcagccta ggggacaggg ctgcttgttc agttattact gcctcggagc 1560
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
 ctccggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
 agggagaaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
 40 tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
 gggggagtggt gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
 ctctatctga ggagccccc ctggtcttca aagcaactta ccaagggtta tttaaagaca 2040
 45 tgaaattttc cagaaatacc atttgggtga tcccttgggt tctgtaatat taaactcagg 2100
 tgaattata ctctgacagt ttctctcttc ctgctcttc cctctgcaga gtcaggacct 2160
 gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaag 2220
 gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggtc 2280
 tcgagttcca aagctctgat gaagaacaa gactccttga tgtgttactg atcccactga 2340
 50 ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400
 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
 ggggtgtcc

<210> 48

55 <211> 1553

<212> DNA

<213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaa taagctttat ttttcatata tatatatatt 60
 ttcatatata tatatata catatataa ggaaacaatt tgcaaattha cacacctgac 120
 aaaacacatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
 ctagccaggc cggttttcca tccctaagta ccatttcttc atttggggcc ttctaggggt 240
 65 ggggccctga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
 tgaaggacag tgtagacctc atctttgtct gctcccgcgt gcctttcagt tttacgtgat 360

5 ccatcaagag ggctatggga gccaaagtga caccggggat tgaggctaata tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttctttt ttttctcga 480
 gacggagtct cgctgtgttg cccaggctgg agtgcaagtgg caccgtctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgccgcct cggcctccca 720
 aagtgtctggg attacagggc tgagccacca cactggccc cggcacgtat ctttaagga 780
 atgacaccag ttctctggct ctgaccaaaag aaaaaatgtc acaggagact ttgaagaggc 840
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tgggtggaagc cagccttttg ggcaggaaac cagctcagag 1020
 aggtaccaca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaag 1080
 aaaaaacacg ttctgcaaga aactctccta ccgctcggg agactggggc tccttgcttg 1140
 ggatgagctt cactcaacgt ggagatgggt gtggactggg ccctgaaaag cgggccttgc 1200
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaagg ggtgtgcagg 1260
 cgaggggagc aggaggcttc tctctagtc ctttgagggc tttggctgag agaagagtga 1320
 gcagggagct gggaatgggc caggcaggga agggagctga agtgattcgg ggctaagtc 1380
 tcagatcgat gtatttctct ccctggtctc ccggagccct cttgtcaccg ctgctgccct 1440
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
 20 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtggtccc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagtggga 60
 tggtgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180
 gcctgtcaga acacttggtt actcctaccc cagatcagtg gacctgggaa tgagggttg 240
 tcccgaggag cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300
 35 gaagcctccc ggggagtgag ccagagcctg gaccgctgtg ctgatgtgtc tgggggtggag 360
 ggaggggtgg gagtggtcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420
 tgcgtgctcg tgtgtgtgct tgcccctccc ctgcagccgt cgggtggtatc tccctccagc 480
 cccttcgcca cttctgagc attgtctgtc cactgagac tgcccagaga cagcagagct 540
 ccacgtggtt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600
 caggtgtctaa atgaccggac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660
 40 gtcccgtcga cctgcccccg tggcgtctca cggtgatgcc tgctcctgac attggtgttc 720
 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780
 ttcaaataaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840
 tactttgacc tcttgcttac aaccccttcc ttgggtccga ggctggtagc tttgttact 900
 45 tcagatgggt gggggcgggt g

<210> 50

<211> 338

<212> DNA

50 <213> Human

<400> 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tcccctccag atattacccc atttctctac tttccattgt agccaaactt tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttcgt 240
 cactgttgctc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgetaca 300
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60 <210> 51

<211> 1191

<212> DNA

<213> Human

65 <400> 51

5 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacacat ccggggatgg 60
 ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tgttggctct ctgtgccact 120
 cctggaaaat aatgaattgg gtaaggaaca gtttaataaga aaatgtgcct tgctaactgt 180
 gcacattaca acaaagagct gccagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300
 tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgctcctg acaagtcggg 360
 aatttctcta tttctccact ggtgcaaaga gcggatttct ccttgcttct cttctgtcac 420
 ccccgctcct ctccccagc aggcctcctg atttatggta gcttggact tgcctccccg 480
 tctgactgtc cttgacttct agaatggaag aagctgagct ggtgaaggga agactccagg 540
 10 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600
 aagacaaact aaagcaccag catttgaaga aaaaggcctt gaggagagaa tggcttctag 660
 atggaatcag cagcggaata gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780
 aaaaagctga actgcaaatc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840
 15 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960
 ctagggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080
 cttccaatac ctctggccat cagatgactt taaaaggtag aggagtaaaa gtttaagatg 1140
 20 atgggcaaaa gtccagtgtg ttcagtaaag tgctaatac aagttggagg t

<210> 52

<211> 1200

<212> DNA

25 <213> Human

<400> 52

30 aacagggact ctactctat caaccccagg ctggagtcgg gtgcgcccac cctggctccc 60
 tgcaacctcc gcctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180
 cgccttctgt ccaggccggc atcatatact ttaaatacatg cccagatgac ttaataacct 240
 aatacaatat atcaggtttg tttaaaaata attgcttttt tattattttt gcatttttgc 300
 35 accaacctta atgctatgta aatagttggt atactgttgc ttaacaacag tatgacaatt 360
 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtgggc tttttttttt 420
 ttctcagtggt tttcaattcc tccttggttg aatccatgga tgcaaaaccc acagatatga 480
 agggctgggt atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540
 atatgtagtg aaagtatttg tacagtggaa agagttagtg aaaacataaa catttgacc 600
 40 tttcaagaaa gtagcttgg tgaagtttt caccttcaaa ctatgtcca gtcagggctc 660
 ttgctaataat tagctataat ctttgacaaa attacatcac ctttgagtct cagttgcctc 720
 acctgtaaaa tgaaagaact ggatactctc taaggctact tccagccctg tcattctata 780
 actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtca aactgaaaat 840
 gattattaaa gtgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900
 gaataactct tccaattttt taagaatttta aatattttta agggtttgac ctattttatt 960
 45 agagatgggg tctcactctg tcacccagac tggagtacag tggcacatc atagctcact 1020
 gctgcctcaa attcatgggc tcaagtatc ctctgcctc tgcctccaga gtagctgcga 1080
 ctatgggcat gtgccaccac gcctggctaa catttgattt gacctattta tttattgtga 1140
 tttatatctt tttttttttt tctttttttt ttttttacia aatcagaaat acttattttg 1200

50 <210> 53

<211> 989

<212> DNA

<213> Human

55 <400> 53

60 aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga cttttatttt 60
 tatgcctttc ttcctatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120
 gattcaatta gtccttgggc tggctgactg tgcaggagtc caggagcct ctacaaatgc 180
 agagtgaact tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttcctcca 240
 ggaatgtgcc atttcagatg cacagcacc atgcagaaaa gctggaattt tccttggaaac 300
 cgactgtgat agaggtgctt acatgaacat gctactgtc tttctttttt tttgagacag 360
 gtttcgcttg tgcccaggct gagtgaatg cgtgatctca ctactgcaa ttccacctcc 420
 aggttcaagc attctcctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480
 65 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaac 540
 cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600

	cgaccggcca	ctactgtctt	tctttgacc	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aatttccaaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttaccgca	gtttggcacc	taagagtatg	acaacagcaa	taaaaagtaa	tttcaaagag	780
	tttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aaatcagtta	840
5	ttaatattat	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgct	ctgtcgccca	gcgggagtgc	actggcgcaa	960
	gcccggctca	ccgcaatctc	tgccaccgc				
	<210>	54					
10	<211>	250					
	<212>	DNA					
	<213>	Human					
	<400>	54					
15	catttcccca	ttgtcctga	tggtgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	tagggaatca	agtccctcac	atgggctatt	aaaactaggt	120
	agtgggtggag	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcagggg	180
	aaagggcatt	cttttaggaac	tgcatctggt	aaccacacac	ttgatccaag	agctagggaa	240
20	acttcagttg						
	<210>	55					
	<211>	2270					
	<212>	DNA					
25	<213>	Human					
	<400>	55					
	gcgccccga	gcagcgccc	cgccctccgc	gccttctccg	ccgggacctc	gagcgaaaga	60
30	ggccccgcgc	ccgcccagcc	ctcgctccc	tgcccaccgc	gcacaccgcg	ccgccacccc	120
	gaccccgctg	cgcaaggcct	gtccgctgca	caccagcttg	ttggcgctct	cgtcgcccgc	180
	ctcgccccgg	gctactcctg	cgcgccacaa	tgagctccc	catcgccagg	gcgctcgcc	240
	tagtgcgtcac	ccttctccac	ttgaccaggc	tggecgctctc	cacctgcccc	gctgcctgcc	300
	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtcgg	gctggtcggg	gacggctgcg	360
35	gctgctgtaa	ggctcgcgcc	aagcagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacacca	ggggctggaa	tgcaacttcg	gcgccaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gtcagagggc	agaccctgtg	aataaactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gcccactgt	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
	ttcctctgtg	tcccgaagaa	ctatctctcc	ccaacttggg	ctgtcccaac	cctcggtggg	660
40	tcaaagttac	cgggcagtg	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
	ccatggagga	ccaggacggc	ctccttggca	aggagctggg	attcgatgcc	tccgaggtgg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggtccc	840
	ctgttttttg	aatggagcct	cgcatcctat	acaacccttt	acaaggccag	aaatgtattg	900
	ttcaaacac	ttcatggctc	cagtgtctcaa	agacctgtgg	aactggatc	tccacacgag	960
45	ttaccaatga	caaccctgag	tgccgccttg	tgaaagaaac	ccggatttgt	gaggtgcggc	1020
	cttgtggaca	gccagtgtac	agcagcctga	aaaagggcaa	gaaatgcagc	aagaccaaga	1080
	aatcccccg	accagtcagg	tttacttacg	ctggatgttt	gagtgtgaag	aaataccggc	1140
	ccaagtactg	cggttcctgc	gtggacggcc	gatgctgcac	gccccagctg	accaggactg	1200
	tgaagatgcg	gttccgctgc	gaagatgggg	agacattttc	caagaacgct	atgatgatcc	1260
50	agtcctgcaa	atgcaactac	aactgcccgc	atgccaatga	agcagcggtt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccagggcaca	1380
	cctagacaaa	caaggagaa	gagtgtcaga	atcagaatca	tgagaaaaat	gggcgggggg	1440
	gggtggtggg	atgggactca	ttgtagaaag	gaagccttgc	tcattcttga	ggagcattaa	1500
	ggtattttcga	aactgccaag	ggtgctgggt	cggatggaca	ctaatagcagc	cacgattgga	1560
55	gaatactttg	cttcatagta	ttggagcaca	tgttactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgttttct	gtttgtaaat	tatttgctaa	gcataatttc	tctaggcttt	1680
	tttccttttg	gggttctaca	gtcgtaaaag	agataataag	attagttgga	cagtttaaa	1740
	ctttttattcg	tcctttgaca	aaagtaaatg	ggagggcatt	ccatcccttc	ctgaaggggg	1800
	acactccatg	agtgtctgtg	agaggcagct	atctgcactc	taaactgcaa	acagaaatca	1860
60	ggtgttttaa	gactgaatgt	tttatttatc	aaaatgtagc	ttttggggag	ggaggggaaa	1920
	tgtaataactg	gaataatttg	ttaatttata	ttcagtga	aaatatttatt	agattttatt	1980
	tatggaatta	accattta	aaagaaatat	ttaccttaata	tctgagtgtg	tgccattcgg	2040
	tatttttaga	gggtgctcaa	agtcattagg	aacaacctag	ctcacgtact	caattatttc	2100
	aacaggactt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
65	ttataccttc	agtagagaaa	agtccttgca	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaaa		

<210> 56
 <211> 1636
 <212> DNA
 5 <213> Human

<400> 56

```

10 cttgaatgaa gctgacacca agaaccgctg gaagagcttg ggcccaaagc aggaaagggg 60
   agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120
   cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatggctcc 180
   tggtttgctt ggtctcaagg aactgcatc gtcaaactga tccccggcc gttggaggag 240
   cagttcatcc cttaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
   cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
15 agcccgctggc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtggcc 420
   gatgtctctt gcctggttct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480
   gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
   agcttcacac ccagtggcag tttgattttg gtctccgctg caccgggataa gactcttcgc 600
   atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660
20 gtttactgct gttccatctc ccagactgc agcatgctgt gctctgcagc tggagagaag 720
   tcggtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
   agcagtgctg tctcttgatg cttctcccc gactctgccc tgcttgctac ggcttcttac 840
   gataccaatg tgattatgtg ggacccctac accggcgaaa ggctgaggtc actccaccac 900
   acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
25 tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
   tgggcctctg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080
   acattttttc cacatggttg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
   tggacagctc ctagggtcct gtcctcactg aagcacttat gccggaagc ccttcgaagt 1200
   ttccctaaca cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260
30 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320
   cctgtcaaag ggagttgctg gaataatggg ccaaacatct ggtcttgcat tgaatatgca 1380
   tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
   tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
   aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
35 aagatggtga aggggtggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
   gacctgtgc tgcgtt
  
```

<210> 57
 <211> 460
 40 <212> DNA
 <213> Human

<400> 57

```

45 ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
   gcctccaggg ggctgcagat gtgtctgagg gtgagccttg tgaaagagaa gacaaaagaa 120
   tggaatgagc taagcagcc gcctgggggtg ggaggccgag cccatttgta tgcagcaggg 180
   ggacagagcc cagcaaggga gcctccattc ccaggactct ggagggagct gagaccatcc 240
   atgcccgcag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
50 aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aaccaacca 360
   gcctcctaga ccacggttct toccatcaat ggaatgctag agactccagc caggtgggta 420
   ccgagctcga attcgtaatc atggtcatag ctgtttcctg
  
```

<210> 58
 55 <211> 1049
 <212> DNA
 <213> Human

<400> 58

```

60 atctgatcaa gaatacctgc cctggctact ctgaggatgt ttctgtccac ttgttcacat 60
   tgaggacca gataccttt tttacagagg cacttgcttg gtctaacaca gacacctcca 120
   tgacgacatg ctggctcaca ttttgagttt ctgcagaagt cccccctcca gcctggacta 180
   cagcagcact ttcccgtagg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
65 gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
   ggatctacaa tttttagtag ttttccattg tgagtctggg tcatactttt actgcttgat 360
  
```

```

5  aaaatgtaaa cttcacctag ttcattctct ccaaatccca agatgtgacc ggaaaagtag 420
   cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
   ggacttttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
   aatctttctg actggcagcc ccggtataca aatccacca ccaaaggacc attactgaat 600
10 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccccttat tatctgtaga 660
   attctggctg atgatctggt ttttcattg gagtctgaac acagtatcgt taaattgatg 720
   tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
   aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttg tatggaataa 840
   ggacggttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
15 aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
   aaaaaccgct cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
   acttcaagaa agactctggc tgttctcaa

<210> 59
15 <211> 747
   <212> DNA
   <213> Human

<400> 59
20 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
   ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
   cttaaataata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcataataa 180
25 gttgttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
   atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcagc 300
   ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
   aaagaagccc ctggcacaaa agattccagt gccctgaag aggctccctt cctcctgtgg 420
   gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
   ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
30 ccaattcaat gccacaccta ctggttaccc tttgagggca tttctccaga cagaagcccc 600
   ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
   gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
   cgcgaattta gtagtaatag cggccgc

```